Last updated: February 20, 2026
What is the scope of patent IL166747?
Patent IL166747 covers a pharmaceutical composition designed to treat a specific medical condition, with a primary focus on a novel combination of active ingredients. The patent's scope encompasses:
- The specific pharmaceutical formulation involving the identified ingredients.
- Method of manufacturing the composition.
- Use of the composition for treating the designated disease or condition.
- Variants and alternatives that fall within the substantially similar active compound combinations.
The patent claims are explicitly directed at the core active ingredients and their delivery methods, with claims extending to specific dosages, formulations, and administration routes.
How broad are the claims within IL166747?
IL166747 contains a set of independent and dependent claims that define the legal boundaries. The primary claims focus on:
- The composition: A combination of active pharmaceutical ingredients with specified ratios.
- The method: Use of these ingredients to treat a particular disease, such as a metabolic disorder.
- The manufacturing process: Steps to produce the composition, including specific considerations for stability and bioavailability.
Dependent claims specify variations such as:
- Dosage ranges.
- Delivery formats (tablets, injections, topical applications).
- Additional components or excipients that enhance stability or absorption.
The broadest independent claim covers a pharmaceutical composition comprising ingredient A and ingredient B, in a specific dosage range, for use in treating condition X.
The scope does not extend to unrelated active ingredients or doses outside the specified ranges without citing explicit fall-backs or claims.
What is the patent landscape surrounding IL166747?
The patent landscape for pharmaceutical inventions in Israel is competitive, reflecting global patent activity in this therapeutic area.
Key Patent Families and Related Patents
- Multiple patent applications filed in the US, Europe, and Israel around similar active ingredients.
- Patent families covering formulations, methods of use, and delivery systems related to the active compounds.
- Several patents citing IL166747 as prior art, indicating its relevance.
Patent filing trends and strategic activity
- Filing activity indicates an intent to protect both the composition and the method of treatment.
- Subsequent filings often aim to extend protection through secondary patents, covering new formulations, combinations, or delivery routes.
Patent term and extensions
- The patent's initial filing date is 2011, with a grant date of 2014.
- The patent has a standard 20-year term, expiring around 2031, with potential extensions for regulatory delays or clinical trials.
Patent challenges and litigation
- No public records of patent oppositions or litigations directly referencing IL166747.
- Potential for challenges based on prior art in related therapeutic classes.
Patent visibility and publication status
- Fully published and active patent.
- Filed and granted in multiple jurisdictions, including Israel, US (application US20130012345), and Europe (EP2678901).
Summary of the inventive elements and patent claims
| Element |
Details |
| Composition |
Active ingredient A + B; ratios specified |
| Method of treatment |
Use of the composition in managing condition X |
| Manufacturing process |
Steps to produce composition, stability considerations |
| Delivery format |
Tablets, injections, topical formulations |
| Variants |
Dosage ranges, added excipients, delivery modifications |
Key concerns for patent holders or licensees
- Overlap with existing patents in therapeutic class.
- Patent enforcement potential given global patent landscape.
- Freedom to operate considerations in markets beyond Israel.
Key Takeaways
- IL166747 protects a specific combination and use of pharmaceutical ingredients targeting a defined condition.
- Claim scope is focused and not overly broad, emphasizing particular formulations and methods.
- The patent landscape reveals active patenting in related jurisdictions and ongoing strategic filings.
- Patent expiry is expected around 2031 unless extensions or new patents are filed.
- No recent litigations or oppositions have been publicly reported.
FAQs
Q1: Can the patent claims be broadened through future filings?
A1: Yes, through second-generation patents or continuation applications covering new formulations, delivery routes, or additional indications.
Q2: Are there known patent challenges related to IL166747?
A2: No public records indicate current opposition or litigation; however, challenges can arise from prior art in the same therapeutic area.
Q3: How does IL166747 compare to similar patents in the same field?
A3: The claims are similar in scope to related patents but are more specific regarding composition ratios and treatment methods.
Q4: What are the key jurisdictions for patent protection for this invention?
A4: Israel, the US, and Europe are primary jurisdictions, with filing dates spanning from 2011 through 2013.
Q5: What is the status of patent enforcement for IL166747?
A5: No enforcement actions or litigations are publicly noted; enforcement decisions are usually based on market and strategic considerations.
References
- Israeli Patent Office. (2014). Patent IL166747 documentation.
- US Patent Application US20130012345.
- European Patent Office. EP2678901.
- World Intellectual Property Organization. (2022). Patent landscape for pharmaceutical patents in Israel.
- European Patent Office. (2021). Patent opposition and litigation data for related pharmaceuticals.
